Protocol of efficacy of bifidobacteria intake on gastrointestinal symptoms in symptomatic type 2 diabetes mellitus patients in abdominis: An open-label, randomized controlled trial (Binary STAR study)
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0295998 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Yoshitaka Hashimoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Gastrointestinal Diseases, Bifidobacterium bifidum, Probiotics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biofermin Pharmaceutical Co., Ltd..
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
This randomized, parallel-group study aims to investigate the effects of the probiotic Bifidobacterium bifidum G9-1 (BBG9-1) on the symptoms of diarrhea or constipation in patients with type 2 diabetes mellitus (T2DM).
Methods
This study will examine 100 patients with T2DM who suffering from symptoms of diarrhea or constipation. Eligible patients will be randomly assigned 1:1 to two groups (group A, BBG9-1 group; group B, control group), after the baseline examination. Patients assigned to group A will receive probiotic BBG9-1 oral administration along with their current treatment for 12 weeks, and patients assigned to group B will continue the current treatment for 12 weeks without probiotic BBG9-1 oral administration. Subsequently, examinations similar to the baseline examinations will be performed. The primary endpoint will be a change in the Gastrointestinal Symptom Rating Scale (GSRS) total score from baseline to week 12. Secondary endpoints will include the following: change and percent change in parameters such as GSRS subdomain scores, fecal properties/Bristol stool form scale, defecation frequency, biomarkers, gut microbiota, and macronutrients and factors that affect GSRS total score or constipation/diarrhea subdomain scores from baseline to week 12.
Discussion
The results of this study will clarify the utility of probiotic BBG9-1 in the treatment of diarrhea or constipation in patients with T2DM. Trial registration jRCTs051220127 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Diabetes and Endocrinology, Matsushita Memorial Hospital, Moriguchi, Japan.
- Department of Diabetology, Kameoka Municipal Hospital, Kameoka, Japan.
ORCID-Profile: Yoshitaka Hashimoto
Förderung
- Biofermin Pharmaceutical Co., Ltd.
Zitieren
APA
Hashimoto, Y., Kobayashi, G., Kitagawa, N., Okada, H., Hamaguchi, M., & Fukui, M. (2024). Protocol of efficacy of bifidobacteria intake on gastrointestinal symptoms in symptomatic type 2 diabetes mellitus patients in abdominis: An open-label, randomized controlled trial (Binary STAR study). PLOS ONE. https://doi.org/10.1371/journal.pone.0295998
Vancouver
Hashimoto Y, Kobayashi G, Kitagawa N, Okada H, Hamaguchi M, Fukui M. Protocol of efficacy of bifidobacteria intake on gastrointestinal symptoms in symptomatic type 2 diabetes mellitus patients in abdominis: An open-label, randomized controlled trial (Binary STAR study). PLOS ONE. 2024. doi:10.1371/journal.pone.0295998
BibTeX
@article{Hashimoto2024,
author = {Hashimoto, Yoshitaka and Kobayashi, Genki and Kitagawa, Noriyuki and Okada, Hiroshi and Hamaguchi, Masahide and Fukui, Michiaki},
title = {Protocol of efficacy of bifidobacteria intake on gastrointestinal symptoms in symptomatic type 2 diabetes mellitus patients in abdominis: An open-label, randomized controlled trial (Binary STAR study)},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0295998}
}
EUVIMED